Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxymorphone hydrochloride
Drug ID BADD_D01649
Description An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.
Indications and Usage For the treatment of moderate-to-severe pain.
Marketing Status Prescription; Discontinued
ATC Code N02AA11
DrugBank ID DB01192
KEGG ID D00844
MeSH ID D010111
PubChem ID 5359390
TTD Drug ID D02NSF
NDC Product Code 0115-1234; 0406-0881; 64896-701; 55700-788; 63552-091; 0115-1231; 63629-1926; 63552-093; 0406-0790; 0054-0284; 42806-331; 72865-131; 51634-0095; 72865-130; 13107-104; 63552-092; 63552-095; 0054-0283; 10702-071; 64896-696; 64896-700; 63552-090; 0115-1233; 0115-1315; 63552-094; 31722-929; 0115-1317; 63552-096; 64896-695; 63629-1925; 64896-698; 0115-1232; 10702-070; 0115-1316; 64896-697; 42806-330; 13107-103; 64896-699; 31722-930
Synonyms Oxymorphone | Oxymorphone Hydrochloride | Oxymorphone HCl | Numorphan | Opana
Chemical Information
Molecular Formula C17H20ClNO4
CAS Registry Number 357-07-3
SMILES CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotension24.06.03.002--
Hypoxia22.02.02.003--
Ileus07.13.01.001--
Insomnia19.02.01.002; 17.15.03.002--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Mental impairment17.03.03.002; 19.21.02.003--Not Available
Miosis17.02.11.002; 06.05.03.003--Not Available
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Orthostatic hypotension17.05.01.020; 24.06.03.004--Not Available
Oxygen saturation decreased13.02.01.004--Not Available
Palpitations02.01.02.003--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Respiratory depression22.02.01.010; 17.02.05.047--Not Available
Respiratory distress22.02.01.012--Not Available
Respiratory rate decreased13.15.01.003--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Sedation17.02.04.005--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Tachycardia02.03.02.007--Not Available
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Mental status changes19.07.01.001--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages